ADVERTISEMENT

Growth

Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations

Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations

Eisai/Biogen’s Alzheimer’s disease medicine Leqembi has been a challenge to launch, but while access to pre-treatment testing has improved, infusion center capacity is impacting US sales.

Novo Nordisk’s Dependence On Semaglutide Increases

Novo Nordisk’s Dependence On Semaglutide Increases

A single molecule was responsible for nearly three quarters of the Danish group’s DKK71.3bn ($10.3bn) Q3 revenues.

BMS Sees Growth Products’ Contributions To Total Revenue Increase In Q3

BMS Sees Growth Products’ Contributions To Total Revenue Increase In Q3

With its two biggest sellers losing exclusivity in 2028, the pressure is on for Bristol Myers Squibb to grow revenue through new products, which made meaningful contributions in Q3.

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

Winning With Partnerships: How To Turn A Three-Decade-Old Biotech Profitable

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.

A Good Quarter For Soon-To-Be Pure-Play Sanofi

A Good Quarter For Soon-To-Be Pure-Play Sanofi

The French major enjoys swift growth from Beyfortus among others, and is unworried by future competition.

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Public Company Edition: Upstream grossed $255m and CAMP4 raised $75m in October’s first initial public offerings. In follow-on offerings, Crinetics and Scholar Rock brought in $500m and $300m, respectively. Also, Turnstone cut 60% of its workforce and Gritstone filed for bankruptcy.

Moderately Optimistic: Rounding Out Deal Making In 2024

Moderately Optimistic: Rounding Out Deal Making In 2024

Dealmaking trends in 2024 point toward a healthier financial ecosystem than in 2023. However, with a challenging three quarters in 2024, enthusiasm should be curbed as 2024 rounds out in a slow and steady manner.

Biopharma Dealmaking: All About The Science And Personal Chemistry

Biopharma Dealmaking: All About The Science And Personal Chemistry

Business development leaders from AstraZeneca and Novartis and a biotech CEO get frank about what they want from the other side, highlighting the need for transparency during competitive negotiations, plus a shared spark of enthusiasm about pursuing novel science.

Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

Finance Watch: Biopharma IPO Queue Grows As Market Conditions Improve

Public Company Edition: Septerna, Apimeds, CAMP4 and Upstream filed paperwork with the SEC aiming to take advantage of renewed investor interest in IPOs. Also, Biohaven closed a $287.5m offering and Grifols subsidiary GigaGen obtained up to $135m from BARDA.

UK’s Maxwellia Looking For £2m Investment To Fuel ‘Next Phase Of Rapid Growth’

UK’s Maxwellia Looking For £2m Investment To Fuel ‘Next Phase Of Rapid Growth’

Maxwellia is inviting 100 investors to contribute to the “development of new healthcare solutions that will benefit millions, while also playing a role in shaping the future of self-care.”